Alvotech Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Alvotech wird ein jährliches Gewinn- und Umsatzwachstum von 41.6% bzw. 16.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 45.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 257.9% betragen.
Wichtige Informationen
41.6%
Wachstumsrate der Gewinne
45.39%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.5% |
| Wachstumsrate der Einnahmen | 16.9% |
| Zukünftige Eigenkapitalrendite | 257.86% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 15 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.
Narrativ-Update • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.Narrativ-Update • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Seeking Alpha • Apr 10
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Summary Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers. Risks center on regulatory delays and high leverage (net debt/aEBITDA 9.3x), which could cap valuation and trigger corrections. Read the full article on Seeking Alpha
Narrativ-Update • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.Narrativ-Update • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.Narrativ-Update • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.Narrativ-Update • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.Narrativ-Update • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.Narrativ-Update • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.Narrativ-Update • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.Narrativ-Update • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.Narrativ-Update • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.Analyseartikel • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Narrativ-Update • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.Analyseartikel • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...Analyseartikel • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...Narrativ-Update • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.Analyseartikel • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...Analyseartikel • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...Neues Narrativ • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.Analyseartikel • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking AlphaAnalyseartikel • May 28
Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...Seeking Alpha • Apr 25
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Summary Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi, allowing the company to compete in the biosimilar market for Humira and Stelara. The company's stock price initially dropped after the FDA rejected Simlandi in 2023, but has since recovered. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million and potential growth in the biosimilar market. Q1 2024 earnings will be announced on May 22 and have the potential to exceed Wall Street's expectations, in my view, setting the company on a long-term path to valuation growth, although significant headwinds remain in play. Read the full article on Seeking AlphaAnalyseartikel • Apr 03
Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Alvotech ( NASDAQ:ALVO ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...Analyseartikel • Mar 24
Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Alvotech ( NASDAQ:ALVO ) just released its latest yearly report and things are not looking great. It was not a great...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 993 | 185 | 45 | 89 | 4 |
| 12/31/2027 | 784 | 134 | -26 | 48 | 5 |
| 12/31/2026 | 661 | 165 | -46 | 34 | 5 |
| 3/31/2026 | 562 | -81 | -242 | -123 | N/A |
| 12/31/2025 | 589 | 28 | -146 | -50 | N/A |
| 9/30/2025 | 573 | 69 | -138 | -26 | N/A |
| 6/30/2025 | 562 | 63 | -140 | -43 | N/A |
| 3/31/2025 | 588 | 97 | -225 | -149 | N/A |
| 12/31/2024 | 492 | -232 | -294 | -237 | N/A |
| 9/30/2024 | 394 | -441 | -301 | -265 | N/A |
| 6/30/2024 | 309 | -618 | -343 | -310 | N/A |
| 3/31/2024 | 114 | -494 | -339 | -301 | N/A |
| 12/31/2023 | 93 | -552 | -359 | -312 | N/A |
| 9/30/2023 | 64 | -596 | -356 | -309 | N/A |
| 6/30/2023 | 65 | -416 | -347 | -299 | N/A |
| 3/31/2023 | 100 | -713 | -411 | -361 | N/A |
| 12/31/2022 | 85 | -514 | -361 | -312 | N/A |
| 9/30/2022 | 96 | 61 | -388 | -319 | N/A |
| 6/30/2022 | 78 | -12 | -345 | -285 | N/A |
| 3/31/2022 | 39 | -42 | -274 | -223 | N/A |
| 12/31/2021 | 40 | -102 | -269 | -228 | N/A |
| 12/31/2020 | 69 | -170 | -86 | -74 | N/A |
| 12/31/2019 | 83 | -210 | N/A | -89 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ALVO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).
Ertrag vs. Markt: ALVO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: ALVO wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: ALVODie Einnahmen des Unternehmens (16.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.6% pro Jahr).
Hohe Wachstumseinnahmen: ALVODie Einnahmen des Unternehmens (16.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ALVODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (257.9%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/20 09:56 |
| Aktienkurs zum Tagesende | 2026/05/20 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Alvotech wird von 9 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |